Disease/Infection News

RSS

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections.

11 Sep 2012

First demonstration of newly developed dual humanized FRGTM KO system against malaria

A novel human liver-chimeric mouse model developed at Oregon Health & Science University and Yecuris Corporation has made possible a research breakthrough at Seattle Biomedical Research Institute that will greatly accelerate studies of the most lethal forms of human malaria.

11 Sep 2012

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Although people often say they have "strep" throat, most sore throats actually are caused by a virus, not streptococcus bacteria, and shouldn't be treated with antibiotics, suggest guidelines published by the Infectious Diseases Society of America (IDSA). Antibiotics are ineffective against viruses.

11 Sep 2012

Methodist Hospital develops new technology to rapidly detect drug-resistant TB

Technology developed by scientists at The Methodist Hospital Research Institute could halve the time it takes to diagnose tuberculosis infection, and also tell doctors in a day or two whether the bacteria are drug resistant -- a process that currently takes weeks. Initial tests of the device were recently described in Scientific Reports, a Nature online journal.

11 Sep 2012

Democrats, Republicans can agree on U.S. accomplishments in global health, development

"With back-to-back Republican and Democratic National Conventions, it's natural to focus on our differences," but "I am heartened to see the bipartisan support that exists for U.S. leadership in the world -- particularly for our global development efforts," Dan Glickman, former secretary of agriculture and chair of the Board of the Center for U.S. Global Leadership, writes in a Politico opinion piece.

11 Sep 2012

Blog features interview with former UNAIDS Executive Director about lessons learned fighting AIDS

PSI's "Global Health Impact" blog features a video interview by the Center for Strategic & International Studies (CSIS) in which "former UNAIDS Executive Director Peter Piot discusses with CSIS Senior Vice President and Director of the Global Health Policy Center J. Stephen Morrison the lessons he has learned in his years fighting AIDS."

11 Sep 2012

Speakers at panel discussion explore policy implications of findings on HIV transmission among MSM

The Center for Strategic and International Studies (CSIS) on Thursday hosted a panel discussion focusing on the policy implications of findings published by the Lancet in a special series on HIV/AIDS and men who have sex with men (MSM), the Center for Global Health Policy's "Science Speaks" blog reports.

11 Sep 2012

Most Asian countries fail to include rotavirus vaccine in national immunization programs citing cost as barrier

"Most countries in Asia have yet to make the rotavirus vaccine part of their national immunization program (NIP), despite a World Health Organization (WHO) recommendation to do so," IRIN reports.

11 Sep 2012

CSL Biotherapies receives U.S. Government contract to supply pandemic vaccine antigens

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced it has been awarded a contract by the United States (U.S.) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

11 Sep 2012

AHRQ-funded project reduces rate of central line-associated bloodstream infections in ICUs by 40%

A unique nationwide patient safety project funded by the Agency for Healthcare Research and Quality (AHRQ) reduced the rate of central line-associated bloodstream infections (CLABSIs) in intensive care units by 40 percent, according to the agency's preliminary findings of the largest national effort to combat CLABSIs to date.

11 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Scientists used genetic sequencing to discover new evidence that the first vaccine shown to prevent HIV infection in people also affected the viruses in those who did become infected. Viruses with two genetic "footprints" were associated with greater vaccine efficacy. The results were published today in the online edition of the journal Nature.

10 Sep 2012

Wall Street Journal examines drug-resistant TB

The Wall Street Journal examines global efforts to stop the spread of drug-resistant tuberculosis (TB) strains, stating, "Global health officials view the emergence of incurable cases of tuberculosis in India as a worrisome evolution in a trend they have been concerned and intensely frustrated about for years -- the rise of drug resistant forms of tuberculosis around the world."

10 Sep 2012

Success and failure in fighting cholera in Haiti

"Almost two years after the deadly disease first appeared in Haiti in the aftermath of the Jan. 12, 2010 earthquake, the story of cholera is one of both success and failure," columnist Catherine Porter writes in a Toronto Star opinion piece.

10 Sep 2012

NIH awards Immunetics $3.7M SBIR contract for Babesia infection blood screening test

Immunetics, Inc., has received a $3.7 million, two year SBIR contract from the National Heart, Lung and Blood Institute, an agency of the National Institutes of Health (NIH), to support clinical trials of a new blood screening test for Babesia infection.

10 Sep 2012

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Study measures cost-effectiveness of on-site rapid HIV testing in drug abuse treatment programs

Less than half of community-based substance abuse treatment programs in the United States currently make HIV testing available on-site or through referral. A new study led by researchers at Weill Cornell Medical College shows the cost-effectiveness of integrating on-site rapid HIV testing into drug treatment programs.

10 Sep 2012

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9.

10 Sep 2012

Dynamic mapping could potentially help fill gaps in influenza research

Influenza outbreaks in the United States typically begin with the arrival of cold weather and then spread in seasonal waves across geographic zones. But the question of why epidemics can vary from one season to the next has baffled scientists.

10 Sep 2012

Disease/Infection News

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

First demonstration of newly developed dual humanized FRGTM KO system against malaria

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Methodist Hospital develops new technology to rapidly detect drug-resistant TB

Democrats, Republicans can agree on U.S. accomplishments in global health, development

Blog features interview with former UNAIDS Executive Director about lessons learned fighting AIDS

Speakers at panel discussion explore policy implications of findings on HIV transmission among MSM

Most Asian countries fail to include rotavirus vaccine in national immunization programs citing cost as barrier

CSL Biotherapies receives U.S. Government contract to supply pandemic vaccine antigens

AHRQ-funded project reduces rate of central line-associated bloodstream infections in ICUs by 40%

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Oxyphenbutazone can kill drug resistant TB

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Wall Street Journal examines drug-resistant TB

Success and failure in fighting cholera in Haiti

NIH awards Immunetics $3.7M SBIR contract for Babesia infection blood screening test

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Study measures cost-effectiveness of on-site rapid HIV testing in drug abuse treatment programs

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

Dynamic mapping could potentially help fill gaps in influenza research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News